[{"address1": "155 Bovet Road", "address2": "Suite 303", "city": "San Mateo", "state": "CA", "zip": "94402", "country": "United States", "phone": "650-561-8600", "website": "https://sagimet.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. George W. Kemble Ph.D.", "age": 61, "title": "Executive Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 484003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David A. Happel", "age": 61, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 506458, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 446494, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Urs  Greber Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lucas  Pelkmans Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joe  Oriti", "title": "Interim Principal Financial Officer & Interim Principal Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Rozek Esq., J.D.", "age": 51, "title": "General Counsel & Chief Compliance Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marie  O'Farrell Ph.D.", "title": "Senior Vice President of Research & Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.45, "open": 6.58, "dayLow": 5.75, "dayHigh": 6.76, "regularMarketPreviousClose": 6.45, "regularMarketOpen": 6.58, "regularMarketDayLow": 5.75, "regularMarketDayHigh": 6.76, "forwardPE": -2.4572651, "volume": 594966, "regularMarketVolume": 594966, "averageVolume": 1472614, "averageVolume10days": 721700, "averageDailyVolume10Day": 721700, "bid": 5.75, "ask": 6.0, "bidSize": 800, "askSize": 1300, "marketCap": 183401424, "fiftyTwoWeekLow": 2.13, "fiftyTwoWeekHigh": 20.71, "priceToSalesTrailing12Months": 91.700714, "fiftyDayAverage": 7.7582, "twoHundredDayAverage": 8.441067, "currency": "USD", "enterpriseValue": 29912380, "floatShares": 13999922, "sharesOutstanding": 30375400, "sharesShort": 1555234, "sharesShortPriorMonth": 621997, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.048800003, "heldPercentInsiders": 0.13438, "heldPercentInstitutions": 0.51141, "shortRatio": 0.48, "shortPercentOfFloat": 0.062800005, "impliedSharesOutstanding": 31895900, "bookValue": 4.275, "priceToBook": 1.3450292, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -26920000, "trailingEps": -1.18, "forwardEps": -2.34, "enterpriseToRevenue": 14.956, "52WeekChange": -0.6394985, "SandP52WeekChange": 0.3288405, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SGMT", "underlyingSymbol": "SGMT", "shortName": "Sagimet Biosciences Inc. - Seri", "longName": "Sagimet Biosciences Inc.", "firstTradeDateEpochUtc": 1689600600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "036364bd-80e6-3704-a7f9-b8281c4b4a2f", "messageBoardId": "finmb_34541828", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.75, "targetHighPrice": 67.0, "targetLowPrice": 37.0, "targetMeanPrice": 50.0, "targetMedianPrice": 46.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 101842000, "totalCashPerShare": 4.448, "totalDebt": 103000, "quickRatio": 20.171, "currentRatio": 20.364, "totalRevenue": 2000000, "debtToEquity": 0.105, "revenuePerShare": 0.431, "operatingCashflow": -24136000, "grossMargins": 1.0, "operatingMargins": -3.726, "financialCurrency": "USD", "trailingPegRatio": null}]